Family · Pharmaceutical analytical standards
Losartan
The founder of the sartans: it was the first angiotensin II AT1 receptor blocker to reach the market, in the mid-1990s. It lowers blood pressure by blocking angiotensin II, a powerful vasoconstrictor. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?In 2006 a Johns Hopkins University study showed that losartan prevented aortic aneurysm in mice with Marfan syndrome, by damping down TGF-beta signalling.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
